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AbstrAct
Introduction The National Comprehensive Cancer 
Network guidelines for adult cancer pain indicate that 
acupuncture and related therapies may be valuable 
additions to pharmacological interventions for pain 
management. Of the systematic reviews related to this 
topic, some concluded that acupuncture was promising 
for alleviating cancer pain, while others argued that the 
evidence was insufficient to support its effectiveness.
Methods and analysis This review will consist of 
three components: (1) synthesis of findings from 
existing systematic reviews; (2) updated meta-
analyses of randomised clinical trials and (3) analyses 
of results of other types of clinical studies. We will 
search six English and four Chinese biomedical 
databases, dissertations and grey literature to identify 
systematic reviews and primary clinical studies. Two 
reviewers will screen results of the literature searches 
independently to identify included reviews and studies. 
Data from included articles will be abstracted for 
assessment, analysis and summary. Two assessors 
will appraise the quality of systematic reviews using 
Assessment of Multiple Systematic Reviews; assess 
the randomised controlled trials using the Cochrane 
Collaboration’s risk of bias tool and other types of 
studies according to the Newcastle-Ottawa Scale. 
We will use ‘summary of evidence’ tables to present 
evidence from existing systematic reviews and 
meta-analyses. Using the primary clinical studies, 
we will conduct meta-analysis for each outcome, by 
grouping studies based on the type of acupuncture, the 
comparator and the specific type of pain. Sensitivity 
analyses are planned according to clinical factors, 
acupuncture method, methodological characteristics 
and presence of statistical heterogeneity as applicable. 
For the non-randomised studies, we will tabulate 
the characteristics, outcome measures and the 
reported results of each study. Consistencies and 
inconsistencies in evidence will be investigated 
and discussed. Finally, we will use the Grading of 
Recommendations Assessment, Development and 
Evaluation approach to evaluate the quality of the 
overall evidence.
Ethics and dissemination There are no ethical 
considerations associated with this review. The findings 
will be disseminated in peer-reviewed journals or 
conference presentations.
PrOsPErO registration number CRD42017064113.
bAckgrOund
For people with cancer, pain is a distressing 
and intractable symptom with a prevalence 
rate of over 70%.1 Two-thirds of patients in 
the advanced stage of cancer suffered from 
pain; more than half of patients undergoing 
anticancer treatment experienced pain and 
nearly 40% of patients after curative treat-
ment still complained about pain. Among 
these patients, 40% graded their pain as 
moderate to severe (Numerical Rating 
Scale (NRS) Score ≥5).2 As the possibility of 
early diagnosis and the improvement of cura-
tive technologies prolong survival time for 
patients affected by cancer,3 the requirement 
for alleviation of pain has been highlighted.4 
Enormous advancements in knowledge of 
cancer pain and pain management have 
been achieved.5 6 Notably, the WHO anal-
gesic ladder offers a systematic approach to 
pain relief.7 8 However, cancer pain control 
remains a critical challenge globally,9 10 
including issues associated with inadequate 
pain relief, analgesic addiction and the side 
effects of pharmacological interventions.11–14 
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Protocol
strengths and limitations of this study
 ► The three components will provide comprehensive, 
clinically relevant assessments of the effectiveness 
and safety of acupuncture and related therapies for 
cancer pain.
 ► The umbrella review will provide a quality-appraised 
overview of existing systematic reviews.
 ► Meta-analyses will provide assessments of the 
randomised controlled trial evidence for specific 
acupuncture therapies and types of cancer pain.
 ► Analyses of non-randomised studies will identify 
consistencies and inconsistencies in evidence 
between study types.
 ► Anticipated limitations include study quality, diversity 
between studies and difficulties in synthesising and 
grading evidence from different types of clinical 
studies.
 o
n
 3 June 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-018494 on 10 December 2017. Downloaded from 
2 He Y, et al. BMJ Open 2017;7:e018494. doi:10.1136/bmjopen-2017-018494
Open Access 
Clinical studies have shown benefits of acupuncture 
and related therapies for supportive and palliative care in 
cancer, by diminishing side effects of conventional thera-
pies, relieving cancer-related concomitant symptoms and 
improving overall quality of life.14–17 Acupuncture and 
acupressure are listed in the National Comprehensive 
Cancer Network oncology guidelines as integrative inter-
ventions for adult cancer pain.18 A detailed guideline 
has been developed for acupuncture application in the 
management of pain and non-pain indications in patients 
with cancer.19
Traditionally, acupuncture involves the manual inser-
tion of fine needles into specific loci on the body and its 
associated techniques include the application of pressure 
without needles (acupressure) and the application of 
heat (moxibustion). More modern techniques include 
electrical stimulation of needles (electroacupuncture) 
and skin areas (transcutaneous electrical nerve stimula-
tion (TENS)), and the application of light lasers instead 
of needles (laser acupuncture).20
An increasing number of randomised controlled 
trials (RCTs) of acupuncture for cancer pain have been 
conducted over the years. From the perspective of 
research design for clinical trials, acupuncture presents 
a range of challenges. Acupuncture included a variety of 
methods and techniques which may not be directly compa-
rable.20 21 It is difficult to blind personnel and participants 
in RCTs. Sham/placebo acupuncture devices have been 
developed, but there is some controversy about whether 
these and other control methods used in acupuncture 
studies are truly inert.21–23 Another issue is whether the 
manipulation technique(s) used by the acupuncturist 
and the number of needles inserted impact on analgesia 
in a manner similar to medication dosage.21 24 Further, 
in traditional acupuncture, the intervention is not stan-
dardised and can be adjusted according to the syndrome 
(Zheng) of the individual patient.25 26 One approach 
to addressing the need to assess acupuncture in real-
istic settings has been the adoption of pragmatic trial 
designs.27 28 Furthermore, in studies of cancer pain, there 
can be considerable variation in the type of cancer and 
likely causes of the pain.29 All these factors present issues 
when assessing the effects of acupuncture and related 
therapies in cancer pain and may limit the extent to 
which meta-analysis approaches are appropriate.
the need for this work
One review concluded the accumulated evidence 
suggested that acupuncture could be beneficial for 
pain and other symptoms in patients with cancer,30 but 
a Cochrane systematic review concluded that evidence 
was insufficient to determine whether acupuncture 
was effective for the management of adult cancer pain. 
The conclusions were limited by small sample sizes and 
heterogeneity in methodology, cancer populations and 
acupuncture techniques.21
There are a number of systematic reviews related 
to acupuncture for cancer pain.21 31–38 One included 
acupuncture for pain relief along with other outcomes,35 
while others discussed acupuncture and other Chinese 
medicine therapies for cancer care.36 37 Of the system-
atic reviews that explicitly evaluated the effectiveness of 
acupuncture for cancer pain management, some included 
RCTs for all types of cancer,33 34 while some specifically 
focused on acupuncture for particular conditions.31 32 38 
Some reviews included Chinese databases32–37 but others 
limited searches to English language databases.21 31 38
All these systematic reviews limited their inclusion 
criteria to RCTs. However, other types of clinical studies 
have been published39 40 and additional RCTs have 
been published in recent years.41–44 Given the variety 
of acupuncture and related therapies in current use in 
integrative cancer therapy and the diversity of cancer 
populations in which acupuncture has been applied, 
there is value in conducting a review that aims at inte-
grating multiple levels of evidence. Systematic reviews 
generally focus on RCTs, but when the RCT evidence 
is not sufficient to address clinical questions, the inclu-
sion of non-randomised studies can provide supporting 
evidence, may improve the generalisability of the conclu-
sions, and can inform decision-makers of the totality of 
the available clinical evidence.45
This study takes an umbrella review approach46 to 
summarise the results of published reviews of acupunc-
ture and related therapies for cancer pain. In addition, 
data from all types of clinical trials will be synthesised 
and analysed to arrive at a comprehensive evaluation of 
the effectiveness of each of the acupuncture and related 
interventions for specific categories of cancer pain.
ObjEctIvEs
Umbrella reviews aim to provide synthesised and appraised 
evidence on a broad topic area for decision-makers 
in healthcare, including patients, physicians and poli-
cy-makers.46 The present study: (1) conducts an umbrella 
review that aims to synthesise the findings of existing 
systematic reviews and meta-analyses46; (2) conducts a 
systematic review and meta-analyses of randomised clin-
ical trials and (3) summarises results of other types of clin-
ical studies in order to assess the broad body of clinical 
evidence, inform clinical practice and identify directions 
for future clinical trials and other research. The following 
questions will be addressed: (1) Are acupuncture and 
related therapies effective for relieving pain associated 
with cancer? (2) Do acupuncture therapies enable reduc-
tion in analgesic consumption? (3) Are the effects (if 
any) related to the specific type or stage of cancer, the 
cancer therapies, degree of pain, the type of intervention 
or other variables?
MEthOds
This protocol was developed according the Preferred 
Reporting Items for Systematic Reviews and Meta-Anal-
yses Protocols statement (online supplementary file 
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1)47 48 and has been registered on PROSPERO (no. 
CRD42017064113). The anticipated start date of this 
study is 01/12/2017.
dEsIgn
This study comprises three main components:
1. An umbrella review of systematic reviews and 
meta-analyses.
2. A systematic review of randomised controlled studies 
with meta-analyses of outcome data (if possible).
3. Summaries of the results of non-randomised clinical 
studies on acupuncture and related therapies for can-
cer pain.
We have performed a scoping literature review of all 
cancer pain-related publications in the Cochrane library. 
This preparatory step helped define the inclusion criteria, 
develop the literature search strategies and determine 
the data to be extracted from eligible reviews and clinical 
studies.
ElIgIbIlIty crItErIA
types of studies
Articles published in English or Chinese including:
1. systematic reviews and/or meta-analyses of the effects 
of acupuncture and related therapies on pain relating 
to cancer;
2. RCTs (with or without blinding) including cross-over 
designs and pragmatic trials;
3. non-randomised studies, including case–control stud-
ies, case series studies, cohort studies, concurrently 
controlled studies, cross-sectional studies, historically 
controlled studies, time series studies and case stud-
ies.45 49
types of participants
Adult participants with cancer pain, including pain 
directly caused by the development of cancer and pain 
related to treatments for cancer.18
types of intervention
We will consider acupuncture and related therapies 
regardless of needling techniques and stimulation 
method, including manual acupuncture, electroacupunc-
ture, ear acupuncture, acupressure, moxibustion, TENS 
and combinations of these. Treatments in the compar-
ison groups can be sham/placebo acupuncture, pharma-
cotherapy or no additional intervention to usual care.50 51
types of outcome measures
We will consider systematic reviews and clinical studies 
that report numerical data on one or more of the 
following outcomes:
1. Patient-reported pain intensity or pain relief mea-
sured using a Visual Analogue Scale, Verbal Rating 
Scale, NRS,52 the McGill Pain Questionnaire,53 the 
Brief Pain Inventory54 or other validated outcome 
measures.55
2. Quality of life measured using validated scales, in-
cluding the European Organisation for Research and 
Treatment of Cancer Quality of Life Questionnaire,56 
the General Version of the Functional Assessment of 
Cancer Therapy,57 the Edmonton Symptom Assess-
ment System58 or other validated scales.59
3. Consumption of analgesics including opioids and 
non-opioids.18
4. Frequency of breakthrough pain60 and rescue medica-
tion use or dosage.
5. Safety of the acupuncture intervention including ad-
verse events and withdrawals for any reason.
sEArch strAtEgy
To identify systematic reviews and/or meta-analyses of 
acupuncture and related therapies for cancer pain, we 
will search PubMed (1966 to present), Embase (1974 to 
present) and CINAHL (1982 to present), JBI Database of 
Systematic Reviews and Implementation Reports (2003 to 
present), the Cochrane Database of Systematic Reviews 
(1992 to present) and the PROSPERO register.46 Consid-
ering that acupuncture is frequently used in China, we 
will search the following Chinese databases: Chinese 
Biomedical Literature Database (CBM, 1978 to present), 
VIP Database for Chinese Technical Periodicals (CQVIP, 
1989 to present), China National Knowledge Infrastruc-
ture (CNKI, 1994 to present) and Wanfang Data (1998 
to present). The search strategy for PubMed/MEDLINE 
database is shown in online  supplementary file 2.
To identify clinical studies, we will search PubMed, 
Embase, CINAHL and the Chinese databases CBM, 
CQVIP, CNKI and Wangfang Data. Search terms will 
generally consist of three groups: (1) clinical condition 
(cancer, tumour, carcinoma, neoplasm, pain, analgesia, 
etc); (2) intervention (acupuncture, electroacupuncture, 
auriculotherapy, acupoint, needle, acupressure, etc) and 
(3) study type (random, controlled trial, cohort, case–
control, comparative study, case series, etc), with adjust-
ments for different databases.61
In addition, we will search clinical trial registries, disser-
tations and grey literature.61
screening and selection
Following the comprehensive searches for systematic 
reviews and clinical studies, two reviewers (YHH and YHL) 
will screen all hits independently based on the titles and 
abstracts. Full texts will be downloaded for further evalu-
ation when necessary. At the next stage, the reviewers will 
examine the full text articles according to the inclusion 
criteria. A third reviewer will be consulted to resolve any 
disagreement by discussion and consensus.62
dAtA ExtrActIOn
All data extraction will be undertaken by two indepen-
dent reviewers (YHH and YHL) who will extract informa-
tion using predesigned forms.
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For systematic reviews, we will extract46 63:
1. identification information (publication year, first 
author);
2. general information (objectives, type of review, target 
condition, comparator);
3. methodological characteristics (included study 
type, any restriction on included studies, databases 
searched and date ranges, methods of data extraction 
and assessment of study quality, meta-analysis meth-
od);
4. participants (inclusion/exclusion criteria, type of can-
cer, type of pain);
5. interventions (type of acupuncture and related thera-
py, type of control intervention);
6. included data (primary and secondary outcomes, 
number of studies, numbers and types of participants, 
country and setting of studies);
7. synthesis method, summary and conclusions.
For all types of clinical studies, we will extract62 64 65:
1. identification information (publication year, first 
author);
2. general information (country, study type, setting, 
number of centres, sample size, study duration);
3. participants (type and/or stage of cancer, age, sex, 
type of pain, pain intensity before treatment, Chinese 
medicine syndrome);
4. interventions (type of acupuncture and related thera-
py, acupuncture point selection, treatment frequency, 
number of sessions, duration of each session, point 
stimulation/manipulation method(s));
5. comparator (if there is any, details of the treatment 
including name, dosage, frequency and course);
6. outcomes (data and time points for each measure-
ment, type and number of adverse events in each 
group).
For both systematic reviews and clinical studies, 
information related to syndrome/pattern of Chinese 
medicine will be extracted, including therapeutic prin-
ciples, Chinese medicine syndrome/pattern and related 
outcomes.66
We will try to contact corresponding authors for any 
missing data or clarification for unclear information.46 62
QuAlIty AssEssMEnt
Two reviewers (YHH and YHL) will appraise the quality 
of the included reviews independently according to the 
Assessment of Multiple Systematic Reviews (AMSTAR) 
tool.67 A systematic review that reports one item in accor-
dance with AMSTAR receives one point with a maximum 
score of 11 points. A score of 8–11 represents high quality, 
while 4–7 means medium quality, and a review with a 
score below 4 is judged as low quality.
The quality of the RCTs will be assessed using the risk 
of bias tool developed by the Cochrane Collaboration. 
We will appraise each study in terms of selection bias 
(random sequence generation and allocation conceal-
ment), performance bias (blinding of participants and 
personnel), detection bias (blinding of outcome assess-
ment) and attrition bias (incomplete outcome data).68
We will carry out quality assessment for non-randomised 
controlled studies according to the Newcastle-Ottawa 
Scale for assessing the quality of non-randomised studies 
in meta-analyses.69 70
Evidence synthesis for systematic reviews
We will report a summary of the findings of the system-
atic reviews and meta-analyses. For each review, this will 
include: the type of acupuncture and related therapies; 
syndrome/pattern in Chinese medicine, the type of 
cancer pain included (related to neoplasm, related to 
cancer therapy); the number of included clinical studies; 
numbers of participants; the outcome measures assessed; 
any meta-analysis results for each outcome, heterogeneity 
and reviewers’ conclusions. ‘Summary of evidence’ tables 
will be used to present syntheses of the overall evidence 
for each type of cancer pain, type of acupuncture inter-
vention, type of control intervention and outcome 
measure.46
Evidence synthesis for rcts
We will use data extracted from published RCTs to 
perform meta-analyses, calculating effect size and 95% CI 
by the random-effects model. Heterogeneity among trials 
will be identified by the χ2 test and reported as I2.71 We will 
assess publication bias using funnel plots and Egger’s test 
for asymmetry when at least 10 trials are available.72
When conducting meta-analysis, for each outcome 
studies will be grouped according to: (1) the type of 
acupuncture (eg, manual acupuncture, electroacupunc-
ture, ear acupuncture, acupressure, moxibustion and 
TENS); (2) the comparator (eg, placebo/sham acupunc-
ture, pharmaceutical therapy, usual care only) and (3) 
the specific type of pain such as breakthrough pain,73 
cancer-induced bone pain74 or aromatase inhibitor-asso-
ciated arthralgia.75
Sensitivity analyses are planned based on clinical 
factors (cancer type, degree of pain, Chinese medicine 
syndrome/pattern), acupuncture method (stimulation 
method, dosage, specific acupuncture points), method-
ological characteristics (sample size, risk of bias), and 
presence of statistical heterogeneity as applicable.
Evidence synthesis for non-randomised studies
First, we will tabulate the characteristics of each of the 
non-randomised studies, the outcome measures and the 
reported results. Where possible, studies will be grouped 
according to study type, type of acupuncture interven-
tion, type of control (if applicable), type of cancer pain 
and study quality.
We will compare the results of the meta-analyses of 
the RCTs with the reported results of non-randomised 
studies when the studies are similar in terms of acupunc-
ture type and type of cancer pain. If the results for the 
effects of the RCTs and non-randomised studies are 
consistent and show the same trend, the evidence from 
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the non-randomised studies may provide support that an 
effect is likely to exist or not exist. On the other hand, if 
the findings from the non-randomised studies are incon-
sistent with the evidence from the RCTs, we should be 
more cautious in the interpretation of the RCT evidence. 
In balancing the two bodies of evidence, we will need to 
take a number of factors into consideration including the 
numbers of participants in the studies, the quality of the 
studies and the clinical relevance of the interventions. In 
synthesising the results of the different types of clinical 
studies, we will consider the non-randomised studies as 
complementary to the RCTs.45
We will use the Grading of Recommendations Assess-
ment, Development and Evaluation approach to evaluate 
the quality of the overall evidence.76
cOncludIng rEMArks
This review will build on previous assessments of the 
evidence for acupuncture and related therapies in the 
management of cancer pain, by synthesising the results 
of previous systematic reviews, conducting updated 
meta-analyses of the outcomes of RCTs, summarising 
evidence from non-randomised clinical studies and 
synthesising evidence from multiple sources.
In assessing the results of non-randomised studies, 
a number of issues will need consideration, including 
the sources of bias in the selection of participants, 
confounding effects of variability in baseline character-
istics, issues relating to potential bias in participant-re-
ported outcomes and the effects of attrition bias.77–80
In synthesising and comparing the results of non-ran-
domised studies and RCTs, we will need to pay attention 
to issues relating to the external validity of the interven-
tions, whether the reported results from these clinical 
studies may be generalised to clinical populations, and 
whether the interventions reflect current clinical prac-
tice.81–83 In cases where no RCT evidence is available for 
a particular intervention, type of cancer pain or outcome 
measure, we will need to base assessments on the avail-
able non-randomised studies while acknowledging the 
limitations of this level of evidence.45 In such cases, the 
non-randomised studies may indicate future directions 
for RCTs, for example, the pilot study on acupuncture 
for cancer-induced bone pain39 and the pragmatic pilot 
study on acupuncture for uncontrolled cancer pain,40 
both suggest that further RCTs are warranted.
Syndrome/pattern (Zheng) differentiation is an 
essential notion in the theory of Chinese medicine 
that informs the selection and application of thera-
peutic interventions.84 RCTs and systematic reviews 
have examined the effects of syndrome differentia-
tion in a number of disorders.85 86 Syndrome distri-
bution among patients with advanced cancer with 
opioid-related constipation has been determined 
by a cross-sectional study87 and treatment based on 
syndrome differentiation has been suggested.66 Where 
possible, this review will examine effects related to the 
application of syndrome/pattern differentiation in 
the include studies and determine any implications for 
future clinical studies.
A likely limitation with the overall quality of the 
evidence is inadequate methodological reporting in many 
articles published in Chinese. Consolidated Standards of 
Reporting Trials and Standards for Reporting Interven-
tions in Clinical Trials of Acupuncture have not been 
adopted by many Chinese language journals and infor-
mation required for assessment of risk of bias may not be 
available in reports of RCTs.88–91 Poor quality of reporting 
in RCTs on acupuncture for cancer pain in Chinese jour-
nals makes it difficult to assess the validity of the results.92 
These issues will be considered when conducting sensi-
tivity analyses based on methodological quality and when 
interpreting results.93
The proposed review has several strengths. The 
umbrella review component will provide an overview 
of the field and identify issues relating to meta-analysis 
in a condition as diverse as cancer pain and highlight 
considerations that will need to be taken into account 
in the systematic review component. A strength of 
the systematic review component is the inclusion of 
multiple Chinese and English language databases 
and grey literature which should ensure a compre-
hensive search of the literature. A further strength 
is any meta-analyses will be informed by rigorous 
methodology as detailed in the Cochrane Handbook 
for Systematic Reviews of Interventions.94 The addi-
tion of the component on non-randomised studies 
will strengthen the overall project by providing an 
extended coverage of the clinical literature which may 
provide supporting evidence to complement the RCT 
literature and fill any clinically relevant gaps.
Anticipated limitations and challenges include 
issues relating the quality of the available evidence 
as outlined above, diversity between clinical studies 
precluding data pooling in meta-analyses, small sample 
sizes limiting confidence in outcomes, and difficulties 
in synthesising and grading evidence from different 
types of clinical studies. Heterogeneity between the 
included studies is likely to lead to bias in the results; 
therefore, we will exercise caution in the interpreta-
tion of the results and take a critical approach when 
assessing the overall evidence.95–97
Despite of these anticipated limitations, evaluating 
the effectiveness of acupuncture for cancer pain is of 
great importance for clinical practice given the chal-
lenges of pain alleviation in patient care.1–3 We will 
consider the issues relating to the scope and overlap of 
systematic reviews included in the umbrella review,98 
whether their conclusions are affected by the results 
of the updated meta-analysis, and whether the results 
reported by the non-randomised studies are consistent 
or inconsistent with the results of the meta-analyses. 
By identifying the strengths, weaknesses and any gaps 
in the available clinical evidence with regard to partic-
ular types of acupuncture interventions or particular 
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outcomes that have been assessed in clinical studies, 
the results of this review can inform future clinical 
research. Furthermore, by conducting a comprehen-
sive evaluation of multiple types of studies, we antici-
pate identifying promising acupuncture interventions 
for specific clinical applications in the management of 
cancer pain.
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